Neurotez announced the execution of an exclusive license agreement covering its Leptin derivatives (Leptin Products), for the treatment of Alzheimer’s disease (AD) and other cognitive disorders, with GCA Therapeutics.
The exclusive license grants GCAT the right to clinically develop and commercialize Leptin Products in mainland China, exclusive of Hong Kong, and Taiwan.
A version of Leptin has recently been approved in the USA for treating generalized lipodystrophy and in Japan for lipodystrophy.
GCAT will assume all development and regulatory responsibility and associated costs for Leptin Products in China, and Neurotez will be eligible to receive gross sales milestones up to US$102.5 million as well as royalties on gross sales.
The exclusive license also has certain minimum annual sales thresholds following first commercial sales in mainland China.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity